Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (August 2024)
34 slides from Volitionrx's investor presentation, August 2024
Slide 1: Corporate Deck August 2024
Corporate Deck August 2024 Property Propertyof ofVolition Volition©©2024 2024 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Our mission is to save lives and improve outcomes
Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Property Propertyof ofVolition Volition©©2024 2024 Slide 3
Slide 4: Summary
Summary • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of or in addition to the genome • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatm
Slide 5: What sets us apart?
What sets us apart? • Our tests are simple, low-cost accessible routine blood tests • Platform agnostic, can be adapted to any diagnostic workflow • Manual, Reference Lab, Specialist Lab and Point of Care Six Hours <10 minutes 45 minutes 20 minutes <15 minutes • Our expanding Intellectual Property p
Slide 6: Commercial Strategy - Licensing
Commercial Strategy - Licensing Overall strategy • R&D conducted by Volition and its research partners • Volition monetizes IP with upfront payments, milestone payments, royalties and sales of key components • Commercialisation via global players and in fragmented markets via regional companies • Ap
Slide 7: The Science Behind Our Technologies
The Science Behind Our Technologies Chromatin Chromosome Nucleosome Cancer and cell death cause chromatin CTCF fragmentation Sequence only present on CTCF in cancer Property of Volition© 2024 Slide 7
Slide 8: Nu.Q Vet Cancer Test
Nu.Q® Vet Cancer Test Property of Volition Veterinary Diagnostics Development© 2024 Slide 8
Slide 9: Licensing & Supply Agreements to-date
Licensing & Supply Agreements to-date • Launched with IDEXX in the U.S Jan ‘23 • Launched in U.S. / Aus • Launched in UK & Ireland Nov ‘23 /HK/Singapore/ some EU countries April ‘24 • Launched July ‘24 • Launched in Portugal • Launched in Nov ‘22 Singapore Nov ‘23 • Launched in Taiwan Nov ‘23 • Laun
Slide 10: Now available in 16 countries and growing
Now available in 16 countries and growing! Property of Volition Veterinary Diagnostics Development© 2024 Slide 10
Slide 11: Launched April 2024
Launched April 2024 Exclusive agreement with Heska providing in- hospital access to Nu.Q® $10M upfront and $13M milestone payments received to-date. $5M milestone payment linked to use in felines remaining Launched APRIL 2024 Ongoing revenue from the purchase of kits and key components Property of V
Slide 12: Launched April 2024
Launched April 2024 Rapid (<10 mins) Accurate (detects 76% of systemic cancers at 97% specificity) Cost effective ($35 to the vet) Allowing veterinarian to make informed clinical decisions quickly – whilst the patient is still in clinic Property of Volition Veterinary Diagnostics Development© 2024 S
Slide 13: Development Pipeline
Development Pipeline Treatment & Disease NETosis in Monitoring animals Application Screening & Platform Monitoring development Cancer in : automated Cats Property of Volition Veterinary Diagnostics Development© 2024 Slide 13
Slide 14: Commercial Performance
Commercial Performance • Received $23 million in upfront and milestone payments to-date • >60,000 tests sold in H1 2024 (including components for the Point-of-Care test) compared to 58,000 sold in 2023 • Test is now available in 16 countries and growing • Target for 2024 is to triple the # of tests
Slide 15: Sepsis & Thrombosis
Sepsis & Thrombosis Property of Volition© 2023 2024 Slide 15
Slide 16: Property of Volition © 2024 Slide 16
Property of Volition© 2024 Slide 16
Slide 17: Sepsis – current challenges
Sepsis – current challenges • The rapid identification and treatment of sepsis significantly improves patient outcomes and reduces complications and long- term morbidity1. • The risk of death from sepsis increases by 7.6% for each hour of delay in appropriate antibiotic therapy2. • CURRENT methods o
Slide 18: Study Overviews & Upcoming Milestones
Study Overviews & Upcoming Milestones • Range of studies from prospective, blinded, longitudinal studies to retrospective analyses of high-quality biobanks from respected groups. • Large Cohort sizes – ranging from 250 to >1700 patients. Total samples for analysis ~ 14,000 • Covering Emergency Depar
Slide 19: Ongoing studies at Centers of Excellence
Ongoing studies at Centers of Excellence Study Principal Description Cohort Size Estimated completion Investigator Over 14,000 samples to process SISPCT Pr. M. Bauer Retrospective analysis of 971 intensive care patients Sample processing & prospectively collected cohort Multiple timepoints data anal
Slide 20: Our focus…
Our focus… To develop a low-cost, routine test to stratify risk of sepsis particularly those at risk of progressing to multiple organ failure; in addition to monitoring the disease progression and response to treatment. Data analysis on several large-scale studies ongoing – results both promising an
Slide 21: Property of Volition © 2024 Slide 21
Property of Volition© 2024 Slide 21
Slide 22: Low-cost, routine and accessible tests
• Low-cost, routine and accessible tests to help detect and monitor disease progression and aid treatment selection Property of Volition© 2024 Slide 22
Slide 23: Study Overviews & Upcoming Milestones
Study Overviews & Upcoming Milestones • Range of studies from prospective and retrospective, blinded, longitudinal studies of lung cancer. • Cohort sizes – ranging from 70 to 800 patients. • Covering detection of lung cancer at diagnosis and during treatment • KEY Outcome measures to demonstrate CLI
Slide 24: Our Focus
Our Focus To develop low-cost, routine tests to help: • detect disease early • provide tailored treatment • assess response to treatment • identify MRD • support continued treatment decisions Many data expected for Confidential Data Room Summer 2024 and expected for publication in H2 2024 Property o
Slide 25: Proof of Concept
Proof of Concept: Potential Breakthrough Cancer Detection Method1. • Novel wet chemistry pathway for ctDNA analysis • Discovered a completely new class of biomarkers that are invisible to current methods and demonstrated that they can be isolated as pure ctDNA • Identified hundreds of potential shor
Slide 26: Summary & Financial Update
Summary & Financial Update Property Propertyof ofVolition Volition©©2024 2024 Slide 26
Slide 27: Commercial Strategy - Licensing
Commercial Strategy - Licensing Overall strategy • R&D conducted by Volition and its research partners • Volition monetizes IP with upfront payments, milestone payments, royalties and sales of key components • Commercialisation via global players and in fragmented markets via regional companies • Ap
Slide 28: Summary
Summary • Diagnostic company focusing on epigenetic markers • Epigenetics = on top of or in addition to the genome • Disease areas – global killers: Cancer, Sepsis; significant market opportunities • Human and Veterinary use cases: • Screening • Monitoring (disease progression and response to treatm
Slide 29: Key Financials Second Quarter 2024
Key Financials Second Quarter 2024 NYSE American Market: VNRX Market Cap: $43.95m* 52-week range: $0.43-$1.38* Net cash used in operating activities:12-month average ~$1.4m/mth** Cash-on-hand: ~$6m** * As of Subsequent to quarter end completed a registered direct offering of Aug 13, 2024 common stoc
Slide 30: Nu.Q Vet Cancer Test Opportunity Simulation
Nu.Q® Vet Cancer Test Opportunity Simulation1. 240 $225m These numbers including our estimated 220 total addressable markets are, of course, subject to fluctuations based on 200 numerous assumptions, which, if prove incorrect could materially impact our 180 estimations and results. *Not revenue guid
Slide 31: Questions?
Questions? Thank you for your interest in Volition. For more details, please visit www.volition.com Property Propertyof ofVolition Volition©©2024 2024 Slide 31
Slide 32: The Team
The Team Property Propertyof ofVolition Volition©©2024 2024 Slide 32
Slide 33: Executive Team
Executive Team Cameron Reynolds MBA, President & Group Chief Executive Officer - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director
Slide 34: Executive Team (continued)
Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King’s College